News coverage about Accelerate Diagnostics (NASDAQ:AXDX) has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 45.6154360290924 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Zacks: Analysts Set $26.50 Target Price for Accelerate Diagnostics Inc (AXDX) (americanbankingnews.com)
- Stocks With Rising Relative Strength: Accelerate Diagnostics (finance.yahoo.com)
- Accelerate Diagnostics Meets 80-Plus Relative Strength Rating Benchmark (finance.yahoo.com)
- ETFs with exposure to Accelerate Diagnostics, Inc. : November 30, 2017 (finance.yahoo.com)
Accelerate Diagnostics (AXDX) opened at $27.10 on Thursday. Accelerate Diagnostics has a 52-week low of $16.75 and a 52-week high of $30.45.
AXDX has been the topic of several research analyst reports. BidaskClub cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, ValuEngine cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $33.00.
In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 61,300 shares of the business’s stock in a transaction on Friday, October 13th. The shares were acquired at an average price of $19.29 per share, for a total transaction of $1,182,477.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack W. Schuler acquired 51,600 shares of the business’s stock in a transaction on Wednesday, October 11th. The stock was acquired at an average price of $20.27 per share, for a total transaction of $1,045,932.00. The disclosure for this purchase can be found here. Insiders have purchased 981,667 shares of company stock worth $18,879,924 in the last quarter. 50.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Accelerate Diagnostics (AXDX) Receives Media Sentiment Score of 0.07” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://ledgergazette.com/2017/12/07/accelerate-diagnostics-axdx-receives-media-sentiment-score-of-0-07.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.